Trial Profile
A Phase 1/2 Study to Assess the Safety and Efficacy of MultiStem Therapy in Subjects With Acute Respiratory Distress Syndrome
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Dec 2021
Price :
$35
*
At a glance
- Drugs Invimestrocel (Primary)
- Indications Adult respiratory distress syndrome
- Focus Adverse reactions; Therapeutic Use
- Acronyms MUST-ARDS
- Sponsors Athersys
- 30 Nov 2021 Results presented in an Athersys media release.
- 30 Nov 2021 According to an Athersys media release, data from this trial has been published in the journal Intensive Care Medicine.
- 23 Sep 2020 According to an Athersys media release, this study will be evaluated through 28 days for the primary clinical assessment and further assessed through a one-year follow-up period.